Poland - Pharmaceutical products

Description

Item 1: Macitentan (10 mg) in the number of 220 packages of 30 tablets each. A requirement of the Contracting Authority is to submit an offer for a medicinal product included in Annex B of the Decree of the Minister of Health on reimbursed medicines, foodstuffs for special nutritional use and medical devices, valid as of the date of submission of offers. The offered price of a medicinal product may not exceed the financing limit specified in the MZ announcement. 1. Aciclovirum (inj., 250 mg) in 100 packs of 10 vials/amp. 2. Amoxicillinum + Acidum clavulanicum (tabl. pl.., Amoxicillinum + Acidum clavulanicum (Table of Coatings, 625 mg) in the quantity of 50 packages of 14 tablets each; 4. Amoxicillinum + Acidum clavulanicum (Table of Coatings, 625 mg) in the quantity of 20 packages of 21 tablets each; 5, Amoxicillinum + Acidum clavulanicum (inj. 1.2 g) in the number of 150 packs of 5 vials each. The contracting authority requires a bid for medicinal products from one manufacturer within the same international name and route of administration, due to the necessity to combine doses. Item 1. Riociguat (Table of Coat 0.5 mg) in the number of 6 packages of 42 tables; Item 2. Riociguat (Table of Coat 1 mg) in the number of 12 packages of 42 tables; Item 3. Riociguat (Table of Coat) in the number of 12 packages of 42 tables; Item 3. over 1.5 mg) in the number of 70 packs of 42 tables; item 4. Riociguat (over 2 mg table) in the number of 120 packs of 42 tables; item 5. Riociguat (overlay table) in the number of 120 packs of 42 tables; item 5. 2.5 mg) in the number of 280 packages of 42 tablets each; the Contracting Authority's requirement is to submit an offer for a medicinal product included in Annex B of the Decree of the Minister of Health on reimbursed medicines, foodstuffs for special nutritional use and medical devices, valid as of the date of submission of offers. The offered price of a medicinal product may not exceed the financing limit specified in the MZ announcement. 1) Proxymetacainum (0.5 % ocular drops) in 2 500 packs of 15 ml each; 2) Brinzolamidum (1 % ocular drops) in 80 packs of 5 ml each; 3. Neomycinum (ointment 0.5 %) in 150 packs of 3 g each; 4. Phenylephrinum (eye drops 10 %) in 1 100 packs of 10 ml each; 5. Ofloxacinum (eye drops 0.3 %) in 1 200 packs of 5 ml each; 6. Troxerutinum (50 mg/ml ocular drops) in 30 packs of 10 ml each;7. Solcoseryl or equivalent (8.3 mg/g eye gel) in 20 packs of 5 g;8. Bimatoprostum + Timolum (0.3 + 5 mg/ml eye drops) in the number of 30 packages of 3 ml each;10. Retinolum (250 IU/g eye ointment) in the number of 12 packages of 5 g each. 1. live Bacillus Calmette-Guerin strains in the form of a closed system for reconstitution and administration to the bladder in the amount of 850 packages 1. Toxinum botulinicum type A with registration indications for the treatment of bladder displacement hyperreactivity (inj, 100 units) in the amount of 150 violetsThe Contracting Authority's requirement is to submit an offer for a medicinal product located in the current as of the date of submission of offers to the Notice of the Minister of Health on reimbursed medicines, foodstuffs for special nutritional purposes and medical devices. The offered price of a medicinal product may not exceed the financing limit specified in the MZ announcement. Calcium (sparkling tablets 1.373 g = 0.177 g of calcium) in the quantity of 50 in packages of 12 tablets;3. Phosphomycinum (bag with granulate 3 g) in the quantity of 50 in packages of 1 sachet;4. Posterisan H or equivalent (composite ointment) in the quantity of 20 in packages of 25 g;5. Posterisan H or equivalent (suppositories compound preparation) in the amount of 10 suppositories each;6. Somatostatinum (inj. 3 mg) in the amount of 36 suppositories of 1 vial each;7. Dextromethorphanum (cap. Levetiracetamum (oral liquid 100 mg/ml) in the amount of 24 in 150 ml packs;9. Levetiracetamum (inj. 500 mg) in the amount of 12 packs of 10 vials;10. Levetiracetamum (Table of coatings: "Levetiracetamum") in the amount of 12 in the packs of 10 vials. 500 mg) in the quantity of 12 in packs of 50 tablets;11. Chlorpromazinum (drops of 4 %) in the quantity of 12 in packs of 10 g;12. Fluticasonum (cream 0.05 %) in the quantity of 30 in packs of 15 g;13. Dexamethasonum (table: Dexamethasonum) in the quantity of 30 in packs of 15 g;13. Dexamethasonum (table 1 mg) in the amount of 450 in the amount of 450 in the amount of 20 tablets each;15. Midazolamum (table 7.5 mg) in the amount of 1 000 in the amount of 1 000 in the amount of 10 tablets each;16. Acidum fusidicum (cream 2 %) in the amount of 30 in packs of 15 g;17. Glucagonum (inj. 1 mg) in the amount of 40 in packs of 1 vial;18. Iruxol Mono or equivalent (composite ointment) in the amount of 250 in packs of 20 g;19. Ketoprofenum (gel 2.5%) in the amount of 300 in packages of 100 g;20. Lactobacillus rhamnosus (amp. 2 billion CFU) in the amount of 50 in packages of 50 amp;21. Lactobacillus rhamnosus (fiol.10). Bupivacainum + Epinephrinum (inj. 5 mg + 0.005 mg /1 ml) in the quantity of 150 in the packs of 5 vials and 20 ml;23. Metronidazolum (gel 1 %) in the quantity of 40 in the packs of 15 g;24. Dexadent or equivalent (composite ointment) in the quantity of 40 in the packs of 5 g. Anidulafunginum (inj. 100 mg) in 120 vials. 1. Micafunginum (inj. 100 mg) in 120 vials. 1. Cefepimum (Inj. 1 g) At 400 vials;2. Cefepimum (inj. 2 g) At 400 vials! Both doses of the drug must come from one manufacturer because of the need to combine doses. 1. 2-compartment bags containing no fat emulsion in 450 packages;2. 3-compartment bags intended for administration via the peripheral vein in the amount of 1 650 packages;3. 3-compartment bags intended for administration via the central vein in the amount of 600 packages;4. parenteral feeding additives in the amount of 20 packages (1 op. a 10 amp. 10 ml);5. Intravenous mannitol solutions of 36 000 packages. 1. normal human immunoglobulin for intravenous administration (inj. 2,5 g/50 ml) in 300 vials 1. Pegfilgrastim (inj. 6 mg/0,6 ml) in 350 amp. - It is a requirement of the Contracting Authority to submit an offer for a medicinal product included in Annex C, valid as of the date of submission of offers of the Notice of the Minister of Health concerning reimbursed medicines, foodstuffs for special nutritional purposes and medical devices. The offered price of a medicinal product may not exceed the financing limit specified in the MZ announcement. Abciximab (inj. 10 mg/5 ml) in 200 vials. 1. Immunoglobulinum humanum anti-D (inj. 300 mcg) in 600 packs of 1 amp each. - teat. Iopromidum (inj. 370/50 ml) In 300 packs of 50 ml2. Iopromidum (inj. 370/100 ml) 8 000 paclitaxel in the form of a nanoparticle complex with albumin (inj. 100 mg) in the amount of 300 vials. It is a requirement of the Contracting Authority to submit a tender for a medicinal product included in Annex B valid as of the date of submission of tenders of the Notice of the Minister of Health concerning reimbursed medicines, foodstuffs for special nutritional use and medical devices. The offered price of a medicinal product may not exceed the financing limit specified in the MZ announcement. Fidaxomycinum (table: 200 mg) in 12 packs of 20 tables 1. N(2)-L-alanyl-L-glutaminum (inj. 200 mg/ml) in 1000 packs of 100 ml. 1. Nadroparinum calcicum (inj. 2 850 IU/0,3 ml) In 1 000 packs of 10 amp. - Nadroparinum calcicum (inj. 3 800 IU/0,4 ml) In 1 500 packs of 10 amp. - Nadroparinum calcicum (inj. 5 700 IU/0.6 ml) In 600 packs of 10 amp. - Nadroparinum calcicum (inj. 7 600 IU/0.8 ml) In 200 packs of 10 amps. - Nadroparinum calcicum (inj. 9 500 IU/ml) In 200 packs of 10 vials and 5 ml. Immunoglobulinum humanum anti-D (inj. 50 mcg) in 250 packs of 1 amp. 2. Immunoglobulinum humanum anti-D (inj. 150 mcg) in 300 packs of 1 amp. Imipenemum + Cilastatinum (inj. 500 + 500 mg) in 1,000 packs 20 tablets 1. Carbacholum (0.01 % intra-knob inj.) in 160 packs of 12 vials and 1.5 ml 1. Misoprostolum (vaginal system 200 mcg) in 60 packs of 5 inserts each 1. Ranibizumabum (intra-knob inj. 2.3 mg/0.23 ml) in 400 vials 1. Afliberceptum (inj. The Contracting Authority's requirement is to submit an offer for a medicinal product included in Annex B of the Decree of the Minister of Health on reimbursed medicines, foodstuffs for special nutritional purposes and medical devices, valid as of the date of submission of offers. The offered price of a medicinal product may not exceed the financing limit specified in the MZ announcement. Cetuximabum (inj. 100 mg/20 ml) 250 vials2. Cetuximabum (inj. 500 mg/100 ml) In the quantity of 80 vialsThe Contracting Authority requires the submission of an offer for a medicinal product included in Annex B of the current notice of the Minister of Health on reimbursed medicines, foodstuffs for particular nutritional uses and medical devices as of the date of submission of offers. The offered price of a medicinal product may not exceed the financing limit specified in the MZ announcement. 1. Doxorubicinum in the form of a complex with citrate in liposomes (inj. 50 mg) in the number of 100 packages (unit of measurement: 1 op. = 2 vials with drug + vials for preparation of liposomes) A requirement of the Contracting Authority is to submit a tender for a medicinal product included in Annex C of the current announcement of the Minister of Health on reimbursed medicines, foodstuffs for special nutritional use and medical devices as of the date of submission of tenders. The offered price of a medicinal product may not exceed the financing limit specified in the MZ announcement. Pazopanibum (see table 200 mg) in the quantity of 50 in packs of 30 table 2. Pazopanibum (see table 400 mg) in the quantity of 10 in packs of 30 table 3.Pazopanibum (table over 400 mg) in the quantity of 50 in packages of 60 tablets each. A requirement of the Contracting Authority is to submit an offer for a medicinal product included in Annex B of the Decree of the Minister of Health on reimbursed medicines, foodstuffs for special nutritional use and medical devices, valid as of the date of submission of offers. The offered price of a medicinal product may not exceed the financing limit specified in the MZ announcement. 1. Abirateronum (table over 250 mg) in the number of 160 packages of 120 tablets each. A requirement of the Contracting Authority is to submit an offer for a medicinal product included in Annex B of the current notice of the Minister of Health on reimbursed medicines, foodstuffs for special nutritional use and medical devices as of the date of submission of offers. The offered price of a medicinal product may not exceed the financing limit specified in the MZ announcement. Epoprostenol (inj. 0.5 mg) 100 vials; 2. Epoprostenol (inj. 1.5 mg) 50 vials; it is a requirement of the Contracting Authority to submit an offer for a medicinal product included in Annex B of the Decree of the Minister of Health on reimbursed medicines, foodstuffs for particular nutritional uses and medical devices, valid as of the date of submission of offers. The offered price of a medicinal product may not exceed the financing limit specified in the MZ announcement. 1. Alirocumabum (inj. 150 mg) in 180 packages (unit of measurement of packaging: 2 injectors)A requirement of the Contracting Authority is to submit an offer for a medicinal product included in Annex B of the current announcement of the Minister of Health on reimbursed medicines, foodstuffs for special nutritional use and medical devices as of the date of submission of offers. The offered price of a medicinal product may not exceed the financing limit specified in the MZ announcement.

Opportunity closing date

08 March 2019

Value of contract

£1m-5m